Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2015

View Archived Issues

Sage Therapeutics reports results from completed phase I/II trial of SAGE-547 in SRSE

Daiichi Sankyo reports highlights of fourth quarter of fiscal 2014

Otsuka Pharmaceutical updates progress of first quarter 2015

Cortendo licenses rights to ATL-1103 for endocrinology applications

Blueprint Medicines describes FGFR-4 inhibitors

TopiVert initiates phase I study of TOP-1288 for ulcerative colitis

New model of mature B-cell lymphoma developed, revealing possible treatment strategy

Preliminary first-in-human phase I results presented for RBL-001/RBL-002

Synovo compound SYD-003 has potential for treating prostate cancer

NCCN awarded ImmunoGen's grant for mirvetuximab soravtansine in FR alpha-positive cancers

Actavis launches Namzaric in U.S.

Endpoints not met in phase III study of EBI-005 for dry eye disease

Caltech to use OMT's UniRat to generate nanobodies against HIV-1

FDA grants fast track designation to AG-120 for patients with AML and IDH1 mutation

DNA-YFVax shows promise as an alternative to expensive YFV vaccines

U.S. fast track designations for luspatercept in beta-thalassemia

Endotoxin-induced uveitis model demonstrates dynamic changes in M1 and M2 macrophages

TRF1 identified as a novel target for treating lung cancer

Synta Pharmaceuticals patents SDC-TRAP compounds

Lilly discloses SGLT1 inhibitors

Merck & Co. reports development of GCGR antagonists

Johnson & Johnson expands policy to enhance access to darunavir

FGFR-4 inhibitors reported in Novartis patent

Pluristem's PLX program selected for EMA's Adaptive Pathways pilot project

Durect releases results from phase I study of oral DUR-928

Endo International agrees to acquire Par Pharmaceuticals

PlasmaTech Biopharmaceuticals completes acquisition of Abeona Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...